关于多发性骨髓瘤潜在抑制剂的研究取得了进展
Guoyuan Tang1, Shan Huang2, Ji Luo3
1State Key Laboratory of Southwestern Chinese Medicine Resources, Chengdu University of Traditional Chinese Medicine, Chengdu, 611137, China.
European journal of medicinal chemistry
|October 25, 2023
概括
新的多发性骨髓瘤 (MM) 药物显示出希望,但耐药性和并发症正在上升. 本综述涵盖了当前和未来的MM疗法,包括机制和临床试验进展.
科学领域:
- 血液学的恶性瘤
- 癌症 药物开发 癌症 药物开发
- 免疫治疗是一种免疫疗法.
背景情况:
- 多发性骨髓瘤 (MM) 是一种显著的血液癌症.
- 最近的疗法,如免疫调节药物,蛋白酶体抑制剂和CD38抗体,改善了患者的生存率.
- 然而,药物耐药性和治疗并发症的增加需要持续的研究.
研究的目的:
- 审查多发性骨髓瘤药物在试验中的特征和临床研究.
- 分析药物结构,作用机制,结构-活性关系和临床进展.
- 探索尚未进入临床试验的药物的潜力,并概述未来的开发方向.
主要方法:
- 对当前和新兴多发性骨髓瘤疗法的文献综述.
- 药物特性分析,包括结构,机制和活性.
- 评估临床试验数据和临床前研究.
主要成果:
- 在临床试验中的几种MM药物表现出不同的机制和不同的临床结果.
- 结构-活性关系为药物有效性和潜在的抗药性途径提供了洞察力.
- 新兴疗法显示出克服抗性和减少并发症的前景.
结论:
- 持续开发新的MM疗法对于解决耐药性和改善患者治疗结果至关重要.
- 了解药物机制和结构-活性关系是设计更有效治疗的关键.
- 未来的研究应该专注于针对多发性骨髓瘤的创新治疗策略和组合方法.
更多相关视频
05:32Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice
Published on: January 7, 2019
6.9K
09:41An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells
Published on: July 15, 2015
8.7K
相关概念视频
Targeted Cancer Therapies
7.7K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.7K
Inhibition of Cdk Activity
4.8K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.8K
Differentiation of Common Myeloid Progenitor Cells
3.2K
Common myeloid progenitors (CMPs) are oligopotent cells that can differentiate into granulocytes and macrophages. Granulocytes and macrophages are essential for protecting the body against bacterial, viral, or fungal infections. They migrate from the bone marrow into the circulating blood to reach specific tissue sites where they differentiate and help in immune surveillance. However, they survive only for a few days and must be continuously made available to the organism to maintain a robust...
3.2K
Drugs that Stabilize Microtubules
2.1K
Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
2.1K
Abnormal Proliferation
4.5K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.5K
